Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Weekly RG 012 Injections in Patients with Alport Syndrome
2016-002181-32Phase 2Terminated
- Sponsor
- Regulus Therapeutics
- Start
- Sep 2016
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lademirsen in Alport syndrome, sponsored by Regulus Therapeutics. Started Sep 2016; status: terminated.
02
Drugs
lademirsen
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on 2016-002181-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002181-32.